G-FINDER data portal: tracking funding for global health R&D

The G-FINDER project tracks R&D funding for new products and technologies that address global health challenges disproportionately affecting the world's most disadvantaged populations. The G-FINDER data portal provides open access to all data captured by the G-FINDER project between 2007 and 2023 and is updated annually towards the end of the year.

or select a quick filter:

Impact Global Health uses the data captured by the G-FINDER project to produce a range of independent reports, including the G-FINDER neglected diseases, emerging infectious diseases, and sexual & reproductive health reports. Please include the following reference when citing or using text, figures, or data from this site:
Impact Global Health, G-FINDER data portal, https://gfinderdata.impactglobalhealth.org

HIV R&D funding dropped to an all-time low in 2023, driven by significant decreases from the two top funders: industry and US NIH

Industry investment in late-stage clinical testing of Bedaquiline contributed to highest-ever funding recorded for leprosy R&D

Although still accounting for more than half of total EID funding, COVID investment sharply declined in 2023

Funding for EID-specific platform technologies accounted for a record-high 20% of non-COVID EID investment, jumping from $167m in 2022 to $421m in 2023

Funding for pre-eclampsia and exclampsia R&D rebounded in 2023 to reach $40m, doubling last year's investments and reaching an all-time high

The seven new SRH indications included in this year's survey received a total of $119m in R&D funding in 2023. Most of it was for preterm labour, menopause and endometriosis